PharmaPrint Reports Quarter Loss
PharmaPrint Inc., which develops dietary supplement products and pharmaceuticals from natural plant extracts, reported a net loss of $5.7 million, or 45 cents a share, for the fiscal fourth quarter ended March 31, compared with a net loss of $2.2 million, or 20 cents a share, for the year-earlier period.
For the year, the Irvine company lost $18.1 million, or $1.59 a share, which included a $3.8-million charge for stock compensation expenses. The net loss for the prior fiscal year totaled $11.2 million, or $1.15 a share, which included noncash stock compensation expense charges of $5.3 million. No revenue was reported.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.